Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Venetoclax + Azacitidine in Untreated AML
NCT05079230Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of magrolimab in acute myeloid leukemia (AML), sponsored by Gilead Sciences. Started Jul 2022; status: terminated.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05079230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079230.